Showing 2021-2030 of 6036 results for "".
- Sifi Announces License Agreement with Avanzanite Bioscience for Acanthamoeba Keratitis Treatment Akantiorhttps://modernod.com/news/sifi-announces-license-agreement-with-avanzanite-bioscience-for-acanthamoeba-keratitis-treatment-akantior/2481340/Italy-based Sifi announced that it has partnered with Avanzanite Bioscience, a Dutch specialty pharmaceutical company, to exclusively commercialize and distribute Akantior (polihexanide) in 26 countries within the European Economic Area and Switzerland. Under the terms of the agreement,
- J&J Vision Presents New Data on Myopia, IOLs, Phacoemulsification, Dry Eye Drops, Vision Science and Refractive Technologieshttps://modernod.com/news/jj-vision-presents-new-data-on-myopia-iols-phacoemulsification-dry-eye-drops-vision-science-and-refractive-technologies-at-arvo/2480839/Johnson & Johnson Vision is presenting 26 poster and podium presentations focusing on myopia, cataract, dry eye, vision science, and refractive research at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Live and Virtual Annual Meeting. Johnson & Johnson Vision poster
- Verana Health Unveils Annual Ophthalmic Industry Report that Shows a More Than 80% Glaucoma Surgery Uptake Over 8-Year Periodhttps://modernod.com/news/verana-health-unveils-annual-ophthalmic-industry-report-that-shows-a-more-than-80-glaucoma-surgery-uptake-over-8-year-period/2480793/Verana Health announced the release of its American Academy of Ophthalmology IRIS Registry (Intelligent Research in Sight) Industry Report for 2021 at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting being held April 22-26 in 
- Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 ASCRShttps://modernod.com/news/glaukos-technologies-featured-in-numerous-scientific-abstracts-at-the-2022-ascrs/2480788/Glaukos announced that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 22–26, 2022 in Washington, DC. In addition, Glaukos is sponsoring an educational symposium
- Allergan to Present New Data from its Eye Care Portfolio at ASCRS 2022https://modernod.com/news/allergan-to-present-new-data-from-its-eye-care-portfolio-at-ascrs-2022/2480778/Allergan announced that it will present new data from its eye care portfolio at the 2022 ASCRS annual meeting being held April 22–26 in Washington, DC. Presentations will include new data on Vuity (pilocarpine HCl ophthalmic solution) 1.25%, the first and only
- Oyster Point Pharma to Present New Clinical Data at ASCRS 2022https://modernod.com/news/oyster-point-pharma-to-present-new-clinical-data-at-ascrs-2022/2480775/Oyster Point Pharma announced the presentation of data analyses at the American Society of Cataract and Refractive Surgery (ASCRS), being held on April 22-26. The company-sponsored clinical trials that will be presented highlight the recently approved Tyrvaya (varenicline solution)
- Bausch + Lomb Will Present New Scientific Data During the ASCRS Annual Meetinghttps://modernod.com/news/bausch-lomb-will-present-new-scientific-data-during-the-ascrs-annual-meeting/2480769/Bausch + Lomb announced the presentation of 10 podium presentations and two poster presentations during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, which will take place from April 22-26, 2022 in Washington, DC. The presentations will i
- Orasis Pharmaceuticals to Present New Data on Novel Presbyopia Candidate at ASCRShttps://modernod.com/news/orasis-pharmaceuticals-to-present-new-data-on-novel-presbyopia-candidate-at-ascrs/2480764/Orasis Pharmaceuticals announced that it will present new data on its novel eye drop candidate, CSF-1, at the 2022 American Society for Cataract and Refractive Surgery (ASCRS) annual meeting being held April 22-26 in Washington, D.C. "We look forward to these present
- Oyster Point Pharma Announces Tyrvaya Nasal Spray Now Covered by Express Scriptshttps://modernod.com/news/oyster-point-pharma-announces-tyrvaya-nasal-spray-now-covered-by-express-scripts/2480656/Oyster Point Pharma announced Tyrvaya Nasal Spray’s placement on the Express Scripts National Preferred, Basic, and High Performance Formularies, which collectively covers an estimated 26 million people, effective February 19, 2022. Tyrvaya is the first and only na
- FDA Accepts Santen’s NDA for Cyclosporine Topical Ophthalmic Emulsion for the Treatment of Severe Vernal Keratoconjunctivitis in Patients Ages 4-18https://modernod.com/news/fda-accepts-santens-nda-for-cyclosporine-topical-ophthalmic-emulsion-for-the-treatment-of-severe-vernal-keratoconjunctivitis-in-patients-ages-4-18/2478457/Santen announced that the FDA has accepted the new drug application (NDA) for cyclosporine topical ophthalmic emulsion 0.1% for the treatment of severe vernal keratoconjunctivitis (VKC) in patients ages 4-18. The FDA has set June 26, 2021 as the Prescription Drug Use